IDX 184 (Idenix) in Phase II for Hepatitis C - 23-Jun-2012
Idenix Pharmaceuticals has reported positive data from both an interim analysis of a Phase II study of its drug candidate for Hepatitis C virus , IDX184. The company plans to begin a combination study of the IDX 184 and IDX 719, which has just completed a proof of concept study, by the end of the year.
Related News
Phase II data shows ABT 450/r, ABT 267, ABT 333 (Abbvie) successful in patients with Hepatitis C
Phase III trial of BI 201335 (Boehringer) succesful for Hepatitis C patients
Miravirsen (Santaris Pharma) Phase II trial for Hepatitis C is reported in NEJM
Janssen R&D files TMC 435 to the FDA for Hepatitis C
Pegasys (Roche) European indication expanded by EMA in Hepatitis C to include to children
Positive results from Phase III trial of BI 201335 (Boehringer) for Hepatitis C patients
FISSION and Neutrino studies success for GS 7977 (Gilead Sciences) for Hepatitis C
CHMP recommends Pegasys(Roche) for paediatric use in Hepatitis C
Related Hepatology Information
Hepatology Clinical Guidelines
Entecavir for the treatment of chronic hepatitis B
NICETelbivudine for the treatment of chronic hepatitis B
NICEHepatology Clinical Trials
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Clinicaltrials.gov 20 March 2013New Methods to Measure the Immune Response to Hepatitis B Vaccine
Clinicaltrials.gov 18 March 2013Hepatology Medical Journal Abstracts
Prediction of early allograft dysfunction using serum phosphorus level in living donor liver transplantation
Transplant International 25 January 2013Transcapsular arterial neovascularization of liver transplants increases the risk of intraoperative bleeding during retransplantation
Transplant International 25 January 2013Hepatology Medical Apps
Liver Guide
£1.49
Liver Disease
Free
Advert for Healthcare Professionals only